fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study.
Peter ČižnárMarion RoderickHelen SchneiderovaMiloš JeseňákGergely KrivánNicholas BrodszkiStephen JollesCharles AtissoKatharina FielhauerShumyla Saeed-KhawajaBarbara McCoyLeman YelPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2024)
No safety signals were identified, and the incidence of local AEs declined over the duration of fSCIG 10% treatment. This study supports fSCIG 10% long-term safety in children with PIDs. TRIAL REGISTRATION NUMBER (CLINICALTRIALS.GOV): NCT03116347.